Therapeutic Synergy in B-Cell Lymphoma Treatment

Overview of B-Cell Lymphoma

A recent study published in *Science Translational Medicine* investigates the therapeutic synergy between two drugs targeting cancer genes in a B-cell lymphoma model. Blood cancers are diverse, classified by the specific immune cell type that becomes malignant. B-cell lymphoma is characterized by cancerous mutations in B cells, which are responsible for antibody production, leading to accelerated proliferation due to disrupted growth and death mechanisms.

Classification and Characteristics of B-Cell Lymphoma

B-cell lymphoma can be categorized based on distinct genomic characteristics. One specific type, known as double-hit lymphoma (DHL), is marked by mutations in the MYC and BCL2 or BCL6 oncogenes. In DHL, the upregulation of these oncogenes contributes to the cells’ resistance to apoptosis, highlighting their critical role in the disease’s pathogenesis. Previous studies have established that mutations in MYC and BCL2 can induce lymphoma in murine models.

Preclinical Study and Drug Inhibitors

An Italian research group recently conducted a preclinical study assessing the efficacy of two drug inhibitors targeting these oncogenes in a mouse model, with their findings published in *Science Translational Medicine*. The drugs tested were tigecycline, aimed at inhibiting MYC, and venetoclax, which targets BCL2. Individual treatments with these drugs showed minimal effectiveness in eradicating cancer cells across various B-cell lymphoma cell lines.

Results of Combination Therapy

However, the combination of tigecycline and venetoclax demonstrated significant synergy in effectively targeting cancer cells. The researchers further validated these results in mouse models, including both cell lines and patient-derived double-hit lymphoma. In these models, the combination therapy outperformed single-agent treatments, enhancing mouse survival rates and restricting tumor growth. Remarkably, in the patient-derived double-hit lymphoma model, the combination therapy led to almost complete tumor elimination.

Implications for Future Research

This study illustrates the potential of combining two existing clinical drugs into a single treatment regimen for double-hit lymphoma in a preclinical setting, with implications for future patient therapies. It establishes a foundation for utilizing multiple oncogenic inhibitors to combat double-hit lymphoma effectively. Clinical trials involving patients with double-hit lymphoma will be crucial to determine the efficacy of the tigecycline and venetoclax combination in human subjects. Overall, this research underscores the promise of combining these two drugs, potentially advancing treatment options for this aggressive cancer.

Reference

Ravà M, D’Andrea A, Nicoli P, Gritti I, Donati G, Doni M, Giorgio M, Olivero D, Amati B. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. *Science Translational Medicine*. 2018 Jan 31;10(426):eaan8723.